摘要
目的 分析血清肿瘤标志物联合检测对结直肠癌的诊断价值。方法 选取2021年9月至2022年8月收治的结直肠癌患者25例为观察组,结直肠良性病变25例为对照组1,且同期健康体检者20例为对照组2。比较不同组别血清肿瘤标志物表现,不同临床分期结直肠癌患者肿瘤标志物的水平差异。结果 观察组的血清肿瘤标志物指数均较对照组1、2高,且CA724、CA199存在较大差异(P<0.05)。对直肠癌肿瘤标志物水平检测,CA724、CA199、CEA指数在病情分期延后时出现升高趋势,并且在临床观察中某些人群T4期没有升高趋势(P<0.05)。T4期和T3期的CA50、CA242指标存在差异较小,但是较T1~T2期相比存在明显上升空间(P<0.05)。结论 临床在对结直肠癌患者诊断时利用血清肿瘤标志物联合检验可准确的判定阳性,明确肿瘤标志物不同的分期表现,其检验结果和预后具有相关性。
关键词: 肿瘤标志物分期表现;检验阳性率血清肿瘤标志物联合检验;结直肠癌
Abstract
Objective To analyze the diagnostic value of combined detection of serum tumor markers for colorectal cancer. Methods: From September 2021 to August 2022, 25 patients with colorectal cancer were selected as the observation group, 25 patients with benign colorectal lesions as the control group 1, and 20 healthy people as the control group 2. To compare the serum tumor markers in different groups and the difference of tumor markers in different clinical stages of colorectal cancer patients. Results: The serum tumor marker indexes of the observation group were higher than those of the control groups 1 and 2, and there were significant differences in CA724 and CA199 (P<0.05). In the detection of tumor markers of rectal cancer, the indexes of CA724, CA199 and CEA showed an increasing trend when the disease stages were delayed, and in clinical observation, some people had no increasing trend in T4 stage (P<0.05). There is little difference in CA50 and CA242 indexes between T4 and T3, but there is obvious room for increase compared with T1-T2 (P<0.05). Conclusion : In clinical diagnosis of colorectal cancer patients, the combined test of serum tumor markers can accurately determine the positive, and clarify the different stages of tumor markers. The test results are related to the prognosis.
Key words: Staging manifestations of tumor markers; Test positive rate, combined test of serum tumor markers; Colorectal cancer
参考文献 References
[1] 曹亚萍,赵国栋,刘益,等. 血浆胞裂蛋白9和多配体蛋白聚糖2前体甲基化联合检测与4种血清肿瘤标志物对结直肠癌诊断效果的对比性研究[J]. 中国综合临床,2021,37(2):105-111.
[2] 杨成,沈泓,杨家悦,等. 基于SWATH/DIA联合PRM技术筛选结直肠癌伴2型糖尿病血清诊断标志物的研究[J]. 临床肿瘤学杂志,2021,26(4):352-357.
[3] 章维维,邹红,杨蓉,等. 常规临床检验指标与结直肠癌临床病理参数的关联分析及诊断预测价值[J]. 临床检验杂志,2021,39(3):172-177.
[4] 杨章元,周正菊. 血清外泌体中miR-125a-3p、miR-192、miR-223联合检测对早期结直肠癌的诊断价值[J]. 国际检验医学杂志,2020,41(24):3059-3061.
[5] 陈涛,许海生,杨晓虹. 肿瘤标志物和中性粒细胞与淋巴细胞比值在直肠癌患者术前检测中的临床价值[J]. 临床研究,2020,28(1):48-50.
[6] 于登峰,张文俊,张福杰,等. 术前新辅助化疗联合同步放化疗对局部进展期直肠癌预后及血清标志物影响[J]. 中国中西医结合外科杂志,2021,27(1):36-41.
[7] 姚丽君. CEA和CA19-9早期预测接受5-氟尿嘧啶化疗联合贝伐单抗治疗的转移性结直肠癌患者疾病进展的应用研究[J]. 世界最新医学信息文摘(连续型电子期刊),2019,19(59):179-181,184.
[8] 张杭. 直肠癌新辅助放化疗后肿瘤退缩分级的预后价值及其基于定量蛋白质组学的生物标志物研究[D]. 中国人民解放军海军军医大学,2020.
[9] 杜甜甜,李娟,赵颖慧,等. 长链非编码RNA LINC02474在结直肠癌中的表达特征及对细胞增殖的影响[J]. 山东大学学报(医学版),2021,59(10):57-67.
[10] 开今言,马倩,童颖,等. 血清纤维蛋白降解复合物(DR-70)检测在结直肠癌患者中的诊断价值[J]. 中国癌症杂志,2020,30(4):293-298.
[11] 龙华婧,邱芳华,刘道利,等. 血清肿瘤标记物与多层螺旋CT、肠镜及病理联合检查对结直肠癌的诊断价值[J]. 国际检验医学杂志,2019,40(15):1802-1806,1810.